Engineered induced-pluripotent stem cell derived monocyte extracellular vesicles alter inflammation in HIV humanized mice.

HIV Monocyte bone marrow-liver-thymic (BLT) mouse extracellular vesicles inflammation miRNAs neuroinflammation pluripotent stem cells

Journal

Extracellular vesicles and circulating nucleic acids
Titre abrégé: Extracell Vesicles Circ Nucl Acids
Pays: United States
ID NLM: 101775065

Informations de publication

Date de publication:
2022
Historique:
medline: 1 1 2022
entrez: 17 4 2023
pubmed: 1 1 2022
Statut: ppublish

Résumé

A peripheral inflammatory response can drive neuroinflammation in a number of infections including human immunodeficiency virus (HIV). Monocyte/macrophage (M/Mφ) activation is a hallmark of acute HIV infection and a source of chronic inflammation in a subset of HIV-infected individuals. We sought to decrease peripheral inflammation and M/Mφ transmigration after HIV infection by engineering extracellular vesicles (EV) to antagonize a microRNA (miR) associated with inflammation. We hypothesized that induced pluripotent stem cell (iPSC)-derived monocyte EVs (mEVs), engineered to contain an antagomir to miR-155 (αmiR mEV) would target monocyte inflammation and influence neuroinflammation in an HIV-infected humanized mice. mEVs were characterized by tetraspanins, nanoparticle tracking analysis, electron microscopy, and their preferential entry into circulating monocytes as well as testing for endogenous selected miRNAs. HIV-infected humanized mice were treated with control or antagomir155 mEVs. Plasma viral load was measured plus activation markers on lymphocytes and monocytes and the number of macrophages in the brain was quantified. mEVs preferentially entered peripheral monocytes. HIV infection increased C-C chemokine receptor type 5 (CCR5) and major histocompatibility complex, class II, DR (HLA-DR) expression on T cells and monocytes. Treatments with mEVs did not decrease plasma HIV viral load; however, mEVs alone resulted in a decrease in %CCR5+ and %HLA-DR+ on T cells and an increase in %CCR5+ monocytes. αmiR mEVs decreased %CCR5 on M/Mφ. The mEV-treated HIV-infected mice did not show an increase in macrophage transmigration to the brain. mEVs alone caused an unexpected decrease in lymphocyte activation and increase in monocyte %CCR5; however, this did not translate to an increase in macrophage transmigration to the brain.

Identifiants

pubmed: 37067894
doi: 10.20517/evcna.2022.11
pmc: PMC10104589
mid: NIHMS1824992
doi:

Types de publication

Journal Article

Langues

eng

Pagination

118-132

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI138923
Pays : United States

Déclaration de conflit d'intérêts

DECLARATIONS Conflicts of interest All authors declare not conflicts of interest.

Références

J Virol. 2019 Sep 30;93(20):
pubmed: 31341054
PLoS Pathog. 2012;8(4):e1002649
pubmed: 22511873
J Autoimmun. 2021 Jul;121:102660
pubmed: 34020253
Brain Res Bull. 2022 Mar;180:73-85
pubmed: 34974133
Int J Neuropsychopharmacol. 2022 Apr 19;25(4):328-338
pubmed: 35015859
J Am Acad Dermatol. 2016 May;74(5):974-80
pubmed: 26774690
AIDS Res Hum Retroviruses. 2016 Feb;32(2):109-19
pubmed: 26670361
AIDS Res Hum Retroviruses. 2018 Jul;34(7):580-589
pubmed: 29717615
Sci Rep. 2017 Aug 30;7(1):9954
pubmed: 28855621
Circ Res. 2015 Jun 19;117(1):52-64
pubmed: 25904597
FASEB J. 2016 Sep;30(9):3097-106
pubmed: 27226520
Immunity. 2018 Oct 16;49(4):595-613
pubmed: 30332628
Int J Mol Med. 2020 Oct;46(4):1551-1561
pubmed: 32945344
Mol Neurodegener. 2021 Nov 22;16(1):78
pubmed: 34809709
AIDS. 2010 Jun 19;24(10):1415-23
pubmed: 20495440
Int J Med Sci. 2018 Jan 1;15(1):36-45
pubmed: 29333086
J Extracell Vesicles. 2020 Jun 24;9(1):1783869
pubmed: 32939234
Cells. 2019 Dec 11;8(12):
pubmed: 31835680
Cell Immunol. 2011;267(2):109-23
pubmed: 21292246
J Neuroimmunol. 2004 Dec;157(1-2):93-8
pubmed: 15579285
J Neurovirol. 2014 Dec;20(6):571-82
pubmed: 25227930
PLoS One. 2016 Jul 22;11(7):e0159724
pubmed: 27447824
Gene. 2013 Dec 10;532(1):1-12
pubmed: 23246696
J Immunol. 2018 Jun 15;200(12):4170-4179
pubmed: 29720426
Brain. 2000 Sep;123 ( Pt 9):1874-82
pubmed: 10960051
J Neurosci. 2016 Aug 10;36(32):8516-32
pubmed: 27511021
Front Immunol. 2018 Jan 05;8:1932
pubmed: 29354135
Mol Ther. 2011 Oct;19(10):1769-79
pubmed: 21915101
Brain Behav Immun. 2021 Oct;97:365-370
pubmed: 34284114
Curr Drug Targets. 2016;17(1):15-22
pubmed: 26073859
mBio. 2017 Oct 24;8(5):
pubmed: 29066542
Front Immunol. 2018 Apr 20;9:746
pubmed: 29755454
Cell Death Dis. 2020 Jun 1;11(6):409
pubmed: 32483121
J Clin Invest. 2017 Jan 3;127(1):260-268
pubmed: 27941243
Exp Mol Med. 2021 Apr;53(4):695-708
pubmed: 33879860

Auteurs

Bing Sun (B)

San Francisco VA Health Care System, Department of Laboratory Medicine, San Francisco, CA 94121, USA.

Scott Kitchen (S)

UCLA AIDS Institute, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA 94121, USA.

Norina Tang (N)

San Francisco VA Health Care System, Department of Laboratory Medicine, San Francisco, CA 94121, USA.

Andreas Garza (A)

San Francisco VA Health Care System, Department of Laboratory Medicine, San Francisco, CA 94121, USA.

Sheela Jacob (S)

ATCC, Gaithersburg, MD 20877, USA.

Lynn Pulliam (L)

San Francisco VA Health Care System, Department of Laboratory Medicine, San Francisco, CA 94121, USA.
University of California, San Francisco, Departments of Laboratory Medicine and Medicine, San Francisco, CA 94121, USA.

Classifications MeSH